Product Description
Alalevonadifloxacin (WCK 2349) is a novel l-alanine ester prodrug of levonadifloxacin that is being developed as an oral fluoroquinolone antibiotic. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/29263070/)
Mechanisms of Action: DNA Replication Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Wockhardt
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Healthy Volunteers|Other
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
W-2349-101 | P1 |
Completed |
Other |
2014-12-01 |
|
W-2349-103 | P1 |
Completed |
Healthy Volunteers |
2014-12-01 |
|
W-2349-102 | P1 |
Completed |
Healthy Volunteers |
2014-12-01 |
|
W 771/2349-101 | P1 |
Completed |
Healthy Volunteers |
2013-06-01 |